{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:36:08Z","timestamp":1765370168280,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clinthera.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:56:47Z","timestamp":1680008207000},"page":"364-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association Between High NK-Cell Count and Remission of Primary Membranous Nephropathy: A Retrospective Chart Review and Pilot Study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-2027","authenticated-orcid":false,"given":"Weize","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieru","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Raffetseder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-2900","authenticated-orcid":false,"given":"Jialin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.03.002_bib0001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney international"},{"issue":"9981","key":"10.1016\/j.clinthera.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney international"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nature reviews nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0005","first-page":"126","article-title":"Management of membranous nephropathy in Western countries","volume":"1","author":"Alfaadhel","year":"2015","journal-title":"Kidney diseases (Basel, Switzerland)"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clinical journal of the American Society of Nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney international"},{"issue":"9337","key":"10.1016\/j.clinthera.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000167547","article-title":"Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy","volume":"8","author":"Zucchelli","year":"1988","journal-title":"American journal of nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrology, dialysis, transplantation"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2010-12-326231","article-title":"acDCs enhance human antigen-specific T-cell responses","volume":"118","author":"Martinuzzi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0014","first-page":"70","article-title":"T cell subset alterations in idiopathic glomerulonephritis","volume":"50","author":"Cagnoli","year":"1982","journal-title":"Clinical and experimental immunology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15312","article-title":"Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells","author":"Moreira","year":"2022","journal-title":"European journal of neurology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-008-0719-0","article-title":"NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis","volume":"29","author":"Reis","year":"2009","journal-title":"Rheumatology international"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney international"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0018","first-page":"81","article-title":"Effects of rituximab on lymphocytes and immunoglobulin in the treatment of glomerular disease","volume":"37","author":"Lin","year":"2021","journal-title":"Chinese Journal of Nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-016-1101-3","article-title":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting","volume":"18","author":"Merkt","year":"2016","journal-title":"Arthritis research & therapy"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: core curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"American journal of kidney diseases"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.ircmb.2018.05.009","article-title":"Impact of immunosuppressive drugs on the metabolism of T cells","volume":"341","author":"Pallet","year":"2018","journal-title":"International review of cell and molecular biology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0023","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.clinthera.2023.03.002_bib0024","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase a2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1016\/j.clinthera.2023.03.002_bib25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1016\/j.clinthera.2023.03.002_bib26","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1016\/j.clinthera.2023.03.002_bib27","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1016\/j.clinthera.2023.03.002_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1016\/j.clinthera.2023.03.002_bib29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clinical Journal of the American Society of Nephrology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:15Z","timestamp":1758963495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0149291823000759"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between High NK-Cell Count and Remission of Primary Membranous Nephropathy: A Retrospective Chart Review and Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}